Coriell Life Sciences
Driving Precision Medicine as the New Standard of Care

Fifty percent of patients are on a prescription drug that fails to be effective or causes side effects.

One of the causes of these side effects is variations in DNA, which means people may respond differently when taking the same medication. Genetic variations have rarely been considered in medication treatment plans for acute and chronic conditions, until now.

Unlocking the power of pharmacogenomics, Coriell Life Sciences (CLS) empowers healthcare providers, pharmacists, laboratories, and individuals to better understand the efficacy and safety of medications on a personalized level, paving the way for more effective medical care.

With its industry-leading clinical decision support system (CDSS), GeneDose LIVE™ (GDL), CLS leverages the most extensive knowledge of genetic science to improve health outcomes.

GDL helps healthcare providers choose the safest and most effective medications to eliminate trial-and-error prescribing. Providers can swiftly determine which medications are ineffective or potentially harmful for patients and suggest safer alternatives in real time.

The CDSS’ automated risk-assessment engine is a boon for clinical laboratories performing complex molecular testing, as it converts the results into clinically actionable reports.

Equally commendable is Coriell Life Sciences’ Medication Safety Program—the most comprehensive medication risk management solution on the market—designed for employers, payers, retirement and pension groups, benefits managers, and other population care management providers. This offering is a healthcare benefit that empowers employees or members and their physicians to optimize medication choices now and in the future.

This proven targeted approach significantly improves health outcomes and reduces healthcare spending for individuals and sponsoring organizations. These economic, clinical, and humanistic outcomes have been published in peer-reviewed scientific journals.

CLS makes program implementation easy, from the initial ROI assessment to member communications, at-home DNA test kit delivery, test results delivery, pharmacist consultations, and detailed reporting.

“Driven by our mission to empower a healthier world, we go beyond genetic testing to improve population health, reduce costs, and simplify decision-making,” says Scott Megill, President and CEO of Coriell Life Sciences.

Coriell Life Sciences is unlocking the power of pharmacogenomics and driving a new standard of care that improves health and economic outcomes

A testament to the programs’ efficacies can be found in its success with the Teachers’ Retirement System of the State of Kentucky (TRS). TRS sought an innovative solution to lower healthcare costs while improving the health of their members. Coriell Life Sciences was selected to perform a population risk assessment and found 83 percent of TRS members were on at least one drug known to be affected by genetics. Using deidentified claims data, Coriell Life Sciences was able to give the plan administrators a projection of how much savings the program would generate.

The Medication Safety Program was implemented as a free, voluntary benefit to TRS members. Personalized medication action plans, which outline recommended changes to existing medications and considerations for future medications, were created by specially trained pharmacists utilizing GDL and subsequently shared with members and their physicians. Following medication adjustments, participants’ health improved—evidenced by a significant reduction in healthcare resource utilization—and direct medical charges were reduced by greater than $37 million in fewer than three years.

This case study highlights the scalability and positive impacts of Coriell Life Sciences’ expansive service architecture and delivery capabilities for medication safety and risk reporting and comprehensive medication management. Coriell Life Sciences is exploring new horizons for a healthier world and is driving a new standard of care.